GSK will spend over $800 million developing an Innovation and Manufacturing facility in Pennsylvania.
Filling the funds will help the drugmaker ramp up its activities in Upper Merion Township, on the outskirts of Philadelphia, where the company already has drug discovery and development facilities, state officials said Friday. Starting next year, GSK will demolish existing buildings and construct new facilities.
New buildings scheduled to be built include a biologics production facility to facilitate clinical and commercial supply, as well as a co-located R&D pilot plant “to facilitate tech transfer and process development”, according to the announcement from Pennsylvania Governor Josh Shapiro and Department of Community and Economic Development Secretary Rick Siger. GSK will also construct a central quality control lab and manufacturing science and technology center there.
Integration of Advanced Digital Capabilities
The added commercial and R&D manufacturing at our Upper Merion location with advanced digital capabilities will help support the development and supply of medicines in the future for the benefit of patients,” Regis Simard, president of GSK global supply chain, said in a statement.
GSK has not yet disclosed any additional details of the digital capabilities that will be provided in the new facilities. The company had already announced investments in artificial intelligence and digital technologies at its current five U.S. manufacturing facilities.
The $800 million investment in Upper Merion is expected to bring in more than 300 new jobs in the area in the next five years, according to state officials. GSK will have approximately 4,500 current full-time employees in Pennsylvania.
Building on Previous Regional Expansion
The announcement of the investment follows 13 months after GSK announced plans to build an extra flex factory in Upper Merion to produce medicines for respiratory disease and cancer. GSK’s flex factories are designed to allow rapid change between a variety of medicines – often modular equipment and standardised processes. This expansion was part of an overall investment plan of $1.2 billion.
GSK invested $800 million two years ago to enlarge another facility in Pennsylvania. The initial investment enabled the creation of an R&D pilot plant and a vaccine drug substance facility at a facility in Marietta, Pennsylvania.
GSK’s recent Pennsylvania investment qualifies for tax credits under the Manufacturing Tax Credit program and the Qualified Manufacturing Innovation and Reinvestment Deduction program. Tax benefits are among a slew of incentives that Pennsylvania has been offering to lure investment from drug makers such as Eli Lilly and Johnson & Johnson in recent years.
Strategic Shift: Consolidating and Divesting Global Sites
GSK is investing in Pennsylvania and divesting of other sites. GSK has sold facilities in China, Singapore and Maryland to outsourcing partners, and shut down an antibiotic plant in the U.K. over the last two years. The drugmaker also closed down manufacturing at another Cambridge, Massachusetts, plant and made it into a dedicated research and development facility.
GSK Plans a New Biologics Manufacturing Facility
A central component of the GSK investment is a commercial-scale biologics manufacturing facility designed to support both clinical trials and commercial medicine supply.
The Importance of Biologics in Modern Medicine
Biologics have become an increasingly important part of modern healthcare, offering new treatment options for patients with complex and chronic diseases. Unlike traditional small-molecule medicines, these therapies are produced using biological systems and often require highly specialized manufacturing processes, controlled production environments, and rigorous quality testing.
As demand for advanced therapies grows, pharmaceutical manufacturers are investing in facilities capable of producing complex medicines at commercial scale. These investments can help companies prepare for future demand, support clinical development programs, and improve their ability to deliver treatments to healthcare providers.
Pennsylvania’s expanding manufacturing infrastructure offers an opportunity to support this growth by connecting scientific research, technical expertise, and large-scale production capabilities.
